6月3日 - ** 药物开发商Alto Neuroscience ANRO.N的股价盘前上涨17%至3.04美元
** Alto称已从华盛顿的Chase Therapeutics公司收购了一种抑郁症药物 (link) ALTO-207
** 交易包括175万美元的预付款，根据开发和商业里程碑，大通未来可能获得高达7150万美元的付款。
** 公司称，ALTO-207 将治疗帕金森病的药物普拉克索与治疗耐药性抑郁症的昂丹司琼相结合
** 截至上一交易日收盘，公司股价累计下跌 38.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.